Skip to content

NeoNeuro Wins Building Tomorrow Together, Innovation for Dementia Program

NeoNeuro is thrilled to be the winner of the Innovation in Dementia program, the latest initiative by Roche. We thank Roche and CHEDV for their support.

NeoVentures is pleased to announce that our subsidiary company, NeoNeuro (Paris, France), was successful in obtaining financial support through the “Building Tomorrow Together – Innovation in Dementia” program sponsored by Roche Diagnostics. We were one of four successful companies selected out of over 100 applications. 

This program will support a translation study of the novel, Aptamarker blood test for brain amyloid. The translation study will be performed in collaboration with Professor/Doctor Luis Ruano, Memory and Dementia Consultation Coordinator and Coordinator of the Medical Internship of Neurology at the Centro Hospitalar Entre Douro e Vouga (CHEDV) in Santa Maria da Feira, Portugal. 


We are very excited to be taking this important step forward with this innovative technology towards commercialization in partnership with Roche Diagnostics and CHEDV. At NeoNeuro we are convinced that the development of treatments for Alzheimer’s disease (AD) once cognitive dysfunction appears is too late in the disease cycle to be effective. This is similar to starting to develop cancer treatments by treating late stage cancer. We are committed to support the development of earlier, more effective treatments by enabling rapid, effective and inexpensive blood based testing of brain amyloid as a risk factor for AD. 

To learn more about our innovative Aptamarker platform please contact NeoNeuro at or by visiting their website.

The Aptamarker platform is based on the agnostic screening of aptamers against pools of serum that differ for a phenotype, in this case high versus low brain amyloid based on PET scan data. NeoNeuro applied this analysis to four hundred patient samples provided by the AIBL cohort study in Australia and developed a predictive model based on five Aptamarkers with a sensitivity of 95%, specificity of 83% and AUC of 0.954 with the inclusion of clinical variables for patients exhibiting mild cognitive impairment. The diagnostic test involves exposure of the Aptamarkers to a serum sample followed by qPCR analysis. 

The purpose of this three month pilot study is to identify refinements needed in the platform prior to the creation of the data necessary for regulatory approval in Europe and North America. 

Learn More by Contacting One of Our Teams